Interlace Health and Samsung Collaboration Aims to Enhance Mobile Informed Consent Experience for Patients and Staff
Collaboration between Interlace Health and Samsung enables industry-leading eForm technology to be delivered on state-of-the-art Samsung Tablets, advancing care and promoting smart hospital room initiatives
ST. LOUIS, March 11, 2023 — Interlace Health and Samsung announced today a collaboration focused on delivering better workflows for hospital patients, nurses and doctors.
Interlace Health’s new and enhanced Informed Consent offering, Informed Consent Nova, is a cloud-based solution designed to allow patients to review surgical procedures with their doctors and sign their consent through a fully electronic process. The doctor also signs the consent form on the tablet, and it is immediately archived as part of the electronic health record.
“Joining the power of Informed Consent Nova with state-of-the-art Samsung Tablets provides health systems with an affordable and mobile solution which surpasses paper-based consenting, and the cost and compliance issues associated with them,” said Director of Product Marketing at Interlace Health, Dessiree Paoli.
According to a study from JAMA Surgery, paper consents can cost a typical hospital over $580,000 in labor, delayed surgery starts, printing, scanning and shredding. A signed Informed Consent must be documented before surgery can begin, but the reality is that those forms go missing 66% of the time. This leads to delayed surgeries, upset patients, overwhelmed staff, lost revenue and non-compliance. Interlace Health aims to improve the informed consent experience for patients, staff and providers with an electronic solution that streamlines this critical process.
“We’re excited to work with Samsung who shares in our commitment to provide staff and patients with more mobile options in the quest to achieve “Smart Hospital Rooms”. We are working with our hospital clients to place these smart devices into patient rooms to make consenting an easy and entirely digital process for everyone,” said Chief Commercial Officer at Interlace Health, Art Nicholas.
“Samsung sees great value in working with SaaS partners such as Interlace Health to provide best-in-class solutions for our joint healthcare customers. Informed Consent Nova is another application which benefits from having highly reliable, affordable mobile devices available to patients, nurses and doctors to support more efficient Clinical Workflow & cost-effective care,” said Head of Business Development, Samsung Healthcare Mobile B2B, Trevor Smith.
Interlace Health will be demonstrating Informed Consent Nova on Samsung Tablets at the 2023 HIMSS Global Health Conference & Exhibition at booth 8136.
About Interlace Health
For more than 30 years, Interlace Health has pioneered EHR-integrated eForms, eSignature, and workflow technology. Our trusted solutions and unparalleled support have enabled our 1,500+ healthcare clients to save time, cut costs, reduce errors, and improve experiences. Interlace Health’s platform enables several solutions that are accessible by clinicians and patients inside and outside the walls of the healthcare system. These include Forms on Demand, Patient Intake, and Informed Consent. Visit: interlacehealth.com to learn more.
About Samsung
Samsung operates one of the most advanced medical centers in the world, located in Korea – and applies that expertise in developing digital healthcare solutions that drive staff productivity and improve patient experience in hospital, at home and through virtual care. The Samsung platform empowers providers with innovative smart technologies, through a connected ecosystem of secure mobile devices and signage that are easy to manage and transition seamlessly across clinical workflows. Enhance patient care, streamline critical communications, and raise the visibility of your brand with Samsung advanced, digital solutions for healthcare.
###
Media Contact:
Lauren Ziegler, Director of Marketing Communications
314-677-3765
lziegler@Interlacehealth.com
